RxDoctor Payments DataLook up a doctor →

David Page, MD

Medical Oncology · Portland, ORNPI 1922241140

Payments from drug & device makers

$4,015,831in general payments, 2019–2025

Across 475 payments — averaging $8454.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Merck$3M
  • Eli Lilly$272K
  • Takeda Pharmaceuticals U.S.A., Inc.$261K
  • Bavarian Nordic A/s$191K
  • Genentech USA, Inc.$112K
  • E.r. Squibb & Sons, L.L.C.$79K
  • plus $138K from 15 others

What the payments were for

  • Consulting fees$107,88145%
  • Speaking & faculty fees$83,96035%
  • Travel & lodging$34,95115%
  • Food & beverage$9,1744%
  • Education$2020%
  • Other$1,6961%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,015,831 in reported general payments places this provider in the 85th percentile of 92 medical oncology providers in Oregon.

See all medical oncology providers in Oregon

Medicare billing

Part B allowed, 2024
$32,510
Medicare patients
115
Services billed
489

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IbrancePalbociclib38$584,038
LynparzaOlaparib33$536,003
KisqaliRibociclib Succinate28$437,805
VerzenioAbemaciclib18$349,654
Exemestane56$7,461
Anastrozole186$3,417
Letrozole114$2,474
Oxycodone Hcl19$514
Tamoxifen Citrate25$482
Alendronate Sodium53$440
Gabapentin29$302
Duloxetine Hcl15$218
Prochlorperazine Maleate11$204

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerIbrance$13,124$584,03838 claims
AstraZenecaLynparza$7,714$536,00333 claims
NovartisKisqali$29,124$437,80528 claims
Lilly USA, LLCVerzenio$17,083$349,65418 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 92 medical oncology providers in Oregon.

Other medical oncology in Portland

See the full list for Oregon

Where these figures come from

Is this you, or does something look wrong? →